Emerging drugs for ocular hypertension

Bibliography

• Caprioli J, Coleman AL. Blood pressure, perfusion pressure, and glaucoma. Am J Ophthalmol 2010;149:704-12
   PubMed Web of Science ®Google Scholar
• Obsorne NN. Pathogenesis of ganglion “cell death” in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res 2008;173:339-52
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
   PubMed Web of Science ®Google Scholar
• Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80:389-93
   PubMed Web of Science ®Google Scholar
• Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci 1997;38:83-91
   PubMed Web of Science ®Google Scholar
• Leske MC, Connell AM, Schachat AP, Hyman L; for the Barbados Eye Study Group. Prevalence of open-angle glaucoma. Arch Ophthalmol 1994;112:821-9
   PubMed Web of Science ®Google Scholar
• Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia: the Blue Mountains Eye Study. Ophthalmology 1996;103:1661-9
   PubMed Web of Science ®Google Scholar
• Gordon MO, Torri V, Miglior S, ; Ocular Hypertension Treatment Study Group; European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-9
   PubMed Web of Science ®Google Scholar
• Sommer A, Tielsch JM, Katz J, Racial differences in the cause-specific prevalence of blindness in East Baltimore. N Engl J Med 1991;325:1412-17
   PubMed Web of Science ®Google Scholar
• Varma R, Ying-Lai M, Francis BA, Prevalence of open-angle glaucoma and ocular hypertension in Latinos. Ophthalmology 2004;111:1439-48
   PubMed Web of Science ®Google Scholar
• Leske MC. The epidemiology of open-angle glaucoma. Am J Epidemiol 1983;118:166-91
   PubMed Web of Science ®Google Scholar
• Kass MA, Heuer DK, Higginbotham EJ, The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
   PubMed Web of Science ®Google Scholar
• Leibowitz HM, Krueger DE, Maunder LR, The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol 1980;24(Suppl):335-610
   PubMedGoogle Scholar
• Armaly MF, Kreuger DE, Maunder LR, Biostatistical analysis of the collaborative glaucoma study, I: summary report of the risk factors for glaucomatous visual field defects. Arch Ophthalmol 1980;98:2163-71
   PubMed Web of Science ®Google Scholar
• Quigley HA, Enger C, Katz J, Risk factors for the development of glaucomatous visual field loss in ocular hypertension. Arch Ophthalmol 1994;112:644-9
   PubMed Web of Science ®Google Scholar
• Gordon MO, Beiser JA, Brandt JD, The Ocular Hypertension Treatment Study: baseline factors hat predict the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:714-20
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hussein M, Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Treatment Trial. Arch Ophthalmol 2003;121:48-56
   PubMed Web of Science ®Google Scholar
• Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. Am J Ophthalmol 1996;121:473-83
   PubMed Web of Science ®Google Scholar
• Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol 2003;48(Suppl 1):S17-20
   PubMed Web of Science ®Google Scholar
• Rao VP, Epstein DL. Rho GTPase/Rho kinase inhibition as a novel target for the treatment of glaucoma. BioDrugs 2007;21:167-77
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Kaufman PL. Changes in aqueous humour dynamics with age and glaucoma. Prog Retin Eye Res 2005;24:612-37
   PubMed Web of Science ®Google Scholar
• Johnson M. What controls aqueous outflow resistance? Exp Eye Res 2006;82:545-57
   PubMed Web of Science ®Google Scholar
• Tezel G, Kass MA, Kolker AE, Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma 1997;6:83-9
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Thieme H, Stumpff F. The regulation of trabecular meshwork and ciliary muscle contractility. Prog Retin Eye Res 2000;19:271-95
   PubMed Web of Science ®Google Scholar
• Lutjen-Drecoll E. Morphological changes in glaucomatous eyes and the role of TGFbeta2 for the pathogenesis of disease. Exp Eye Res 2005;81:1-4
   PubMed Web of Science ®Google Scholar
• Heijl A, Leske MC, Bengtsson B, ; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
   PubMed Web of Science ®Google Scholar
• The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol 2000;130:429-40
   PubMed Web of Science ®Google Scholar
• American Academy of Ophthalmology. Preferred practice pattern: primary open-angle glaucoma. American Academy of Ophthalmology, San Francisco (CA); 2005
   Google Scholar
• European Glaucoma Society. Terminology and guidelines for glaucoma. 3rd edition. Dogma, Savona, Italy; 2008
   Google Scholar
• Whitson JT. Glaucoma: a review of adjunctive therapy and new management strategies. Expert Opin Pharmacother 2007;8:3237-49
   PubMed Web of Science ®Google Scholar
• Lichter PR, Musch DC, Gillespie BW, ; CIGTS Study Group. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
   PubMed Web of Science ®Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third or fourth antiglaucoma medication effective? J Glaucoma 2004;13:130-6
   PubMed Web of Science ®Google Scholar
• Burr J, Azuara-Blanco A, Avenell A. Medical versus surgical interventions for open-angle glaucoma [review]. Cochrane Database Syst Rev 2005;18:CD004399
   Google Scholar
• Rein DB, Wittenborn JS, Lee PP, The cost-effectiveness of routine office-based identification and subsequent medical treatment of primary open-angle glaucoma in the United States. Ophthalmology 2009;116:823-32
   PubMed Web of Science ®Google Scholar
• Lee PP, Walt JG, Doyle JJ, A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006;124:12-9
   PubMed Web of Science ®Google Scholar
• Stewart WC, Stewart JA, Nassar QJ, Mychaskiw MA. Cost-effectiveness of treating ocular hypertension. Ophthalmololgy 2008;115:94-8
   PubMed Web of Science ®Google Scholar
• Kymes SM, Kass MA, Anderson DR, ; and the Ocular Hypertension Treatment Study Group. Management of ocular hypertension: a cost-effectiveness approach from the ocular hypertension treatment Study. Am J Ophthalmol 2006;141:997-1008
   PubMed Web of Science ®Google Scholar
• Jampel HD. Glaucoma patients' assessment of their visual function and quality of life. Tr Am Ophth Soc 2001;99:301-17
   PubMedGoogle Scholar
• Ramulu P. Glaucoma and disability: which tasks are affected, and at what stage of disease? Curr Opin Ophthalmol 2009;20:92-8
   PubMed Web of Science ®Google Scholar
• Spaeth G, Walt J, Keener J. Evaluation of quality of life for patients with glaucoma. Am J Ophthalmol 2006;141:S3-14
   PubMed Web of Science ®Google Scholar
• Hawkins AS, Szlyk JP, Ardickas, Comparison of contrast sensitivity, visual acuity,a nd Humphrey visual field testing in patients with glaucoma. J Glaucoma 2003;12:134-8
   PubMed Web of Science ®Google Scholar
• Ivers RQ, Mitchell P, Cumming RG. Visual function tests, eye disease and symptoms of visual disability: a population-based assessment. Clin Exp Ophthalmol 2000;28:41-7
   PubMed Web of Science ®Google Scholar
• Freeman EE, Munoz B, West SK, Glaucoma and quality of life: the Sliabury Eye Evaluation. Ophthalmology 2008;115:233-8
   PubMed Web of Science ®Google Scholar
• McKean-Cowdin R, Wang Y, Wu J, ; Los Angeles Latino Eye Study Group. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology 2008;115:941-8
   PubMed Web of Science ®Google Scholar
• Mills RP, Janz NK, Wren PA, Guire KE. Correlation of visual field with quality of life measures at diagnosis in the Collaborative Initial Glaucoma Treatment Study (CIGTS). J Glaucoma 2001;10:192-8
   PubMed Web of Science ®Google Scholar
• Budenz DL. A clinician's guide to the assessment and management of nonadherence in glaucoma. Ophthalmology 2009;116:S43-7
   PubMed Web of Science ®Google Scholar
• Schmier JK, Covert DW, Robin AL. First-year treatment costs among new initiators of topical prostaglandin analogs. Clin Ophthalmol 2009;3:637-44
   PubMedGoogle Scholar
• Costagliola C, dell'Omo R, Romano MR, Pharmacotherapy of intraocular pressure: part I. Parasympathomimetic, sympathomimetic and sympatholytics. Expert Opin Pharmacother 2009;10:2663-77
   PubMed Web of Science ®Google Scholar
• Von Weber A. Die ursache des glaukoms. Albr Graefes Arch Ophthalmol 1877;23:91-4
   Google Scholar
• Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol 2008;53(Suppl 1):S69-84
   PubMed Web of Science ®Google Scholar
• Walland MJ. Glaucoma treatment in Australia: changing patterns of therapy 1994-2003. Clin Experiment Ophthalmol 2004;32:590-6
   PubMed Web of Science ®Google Scholar
• Hellberg MR, Sallee VL, McLaughlin MA, Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther 2001;17:421-32
   PubMed Web of Science ®Google Scholar
• Krauss HP, Woodward DF. Update on the mechanism of action of bimatoprost: a review and discussion of new evidence. Surv Ophthalmol 2004;49(Suppl 1):S5-11
   PubMed Web of Science ®Google Scholar
• Cantor LB. Clinical pharmacology of bimatoprost. Expert Opin Drug Metab Toxicol 2005;1:151-7
   PubMedGoogle Scholar
• Cantor LB. An update on bimatoprost in glaucoma therapy. Expert Opin Pharmacother 2002;3:1753-62
   PubMedGoogle Scholar
• Stjernschantz J, Alm A. Latanoprost as a new horizon in the medical management of glaucoma. Curr Opin Ophthalmol 1996;7:11-7
   PubMedGoogle Scholar
• Nilsson SF, Drecoll E, Lutjen-Drecoll E, The prostanoid EP2 receptor agonist butaprost increases uveosleral outflow in the cynomolgus monkey. Invest Ophthalmol Vis Sci 2006;47:4042-9
   PubMed Web of Science ®Google Scholar
• Gaton DD, Sagara T, Lindsey JD, Increased matrix metalloproteinases 1, 2, and 3 in the monkey uveoscleral outflow pathway after topical prostaglandin F (2 alpha)- isopropyl ester treatment. Arch Ophthalmol 2001;119:1165-70
   PubMed Web of Science ®Google Scholar
• Bahler CK, Howell KG, Hann CR, Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am J Ophthalmol 2008;145:114-19
   PubMed Web of Science ®Google Scholar
• Costagliola C, dell'Omo R, Romano MR, Pharmacotherapy of intraocular pressure – part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin Pharmacother 2009;10:2859-70
   PubMed Web of Science ®Google Scholar
• Lindsey JD, To HD, Weinreb RN. Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1994;35:242-50
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Toris CB, Gabelt BT, Effects of prostaglandins on the aqueous humor outflow pathways. Surv Ophthalmol 2002;47(Suppl 1):S53-64
   PubMed Web of Science ®Google Scholar
• Hylton C, Robin AL. Update on prostaglandin analogs. Curr Opin Ophthalmol 2003;14:65-9
   PubMedGoogle Scholar
• Konstas AG, Mikropoulos D, Kaltsos K, 24-Hour intraocular pressure control obtained with evening- versus morning-dosed travoprost in primary open-angle glaucoma. Ophthalmology 2006;113:446-50
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CA, Schouten JS, Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 2005;112:1177-85
   PubMed Web of Science ®Google Scholar
• Stewart WC, Konstas AG, Nelson LA, Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology 2008;115:1117-22
   PubMed Web of Science ®Google Scholar
• Walters TR, DuBiner HB, Carpenter SP, Bimatoprost Circadian IOP Study Group: 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004;49(Suppl 1):S26-35
   PubMed Web of Science ®Google Scholar
• Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology 1995;102:1743-52
   PubMed Web of Science ®Google Scholar
• Sherwood M, Brandt J; Bimatoprost Study Groups 1 and 2. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol 2001;45(Suppl 4):S361-8
   PubMed Web of Science ®Google Scholar
• Fellman RL, Sullivan EK, Ratliff M, Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated intraocular pressure: a 6-month, masked, multicenter trial. Ophthalmology 2002;109:998-1008
   PubMed Web of Science ®Google Scholar
• Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
   PubMed Web of Science ®Google Scholar
• Hellberg MR, McLaughlin MA, Sharif NA, Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP Prostaglandin Receptor agonist. Surv Ophthalmol 2002;47(Suppl1):S13-33
   PubMed Web of Science ®Google Scholar
• Grierson I, Millar L, De Yong J, Investigations of cytoskeletal elements in cultured bovine meshwork cells. Invest Ophthalmol Vis Sci 1986;27:1318-30
   PubMed Web of Science ®Google Scholar
• Netland PA, Landry T, Sullivan EK, Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
   PubMed Web of Science ®Google Scholar
• Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997;124:544-7
   PubMed Web of Science ®Google Scholar
• Schumer RA, Camras CB, Mandahl AK. Latanoprost and cystoid macular oedema: is there a causal relation? Curr Opin Ophthalmol 2000;11:94-100
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Khouri AS, Zimmerman TJ, Anterior uveitis associated with latanoports. Am J Ophthalmol 1998;126:37-41
   PubMed Web of Science ®Google Scholar
• Warwar RE, Bullock JD, Ballal D. Cystoid macular oedema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients. Ophthalmology 1998;105:263-8
   PubMed Web of Science ®Google Scholar
• Chang JH, McCluskey P, Missotten T, Use of ocular hypotensive prostaglandin analogues in patients with uveitis: does their use increase anterior uveitis and cystoid macular oedema? Br J Ophthalmol 2008;97:916-21
   Web of Science ®Google Scholar
• Wand M, Gilbert CM, Liesegang TJ. Latanoprost and herpes simplex keratitis. Am J Ophthalmol 1999;127:602-4
   PubMed Web of Science ®Google Scholar
• Kroll DM, Schuman JS. Reactivation of herpes simplex virus keratitis after initiating bimatoprost treatment for glaucoma. Am J Ophthalmol 2002;133:401-3
   PubMed Web of Science ®Google Scholar
• Browning DJ, Perkins SL, Lark KK. Iris cyst secondary to latanoprost mimicking iris melanoma. Am J Ophthalmol 2003;135:419-21
   PubMed Web of Science ®Google Scholar
• Krohn J, Hove VK. Iris cysts associated with topical administration of latanoprost. Am J Ophthalmol 1999;127:91-3
   PubMed Web of Science ®Google Scholar
• Pharmacia and Upjohn. Xalatan (latanoprost ophthalmic solution): prescribing information [online]; 2002
   Google Scholar
• Mitra M, Chang B, James T. Drug points. Exacerbation of angina associated with latanoprost. BMJ 2001;323:783
   PubMed Web of Science ®Google Scholar
• Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother 1998;32:504-5
   PubMed Web of Science ®Google Scholar
• Gandolfi S, Simmons ST, Sturm R, Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001;18:110-21
   PubMed Web of Science ®Google Scholar
• Coakes RL, Brubaker RF. The mechanism of timolol in lowering intraocular pressure. In the normal eye. Arch Ophthalmol 1978;96:2045-8
   PubMed Web of Science ®Google Scholar
• Zhang WY, Li Wan Po A, Dua HS, Azuara-Blanco A. Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol 2001;85:983-90
   PubMed Web of Science ®Google Scholar
• Dickstein K, Hapnes R, Aarsland T. Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24-hour heart rate response in patients on treatment for glaucoma. Am J Ophthalmol 2001;132:626-32
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Kahonen M, Ropo A, Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma. Graefes Arch Clin Exp Ophthalmol 2006;244:1491-6
   PubMed Web of Science ®Google Scholar
• Bron A, Velasque L, Rebica H, Comparison of once-daily nonpreserved timolol and timolol maleate gel-forming solution associated with latanoprost. J Fr Ophtalmol 2004;27(9 Pt 1):971-7
   PubMed Web of Science ®Google Scholar
• Liu JH, Kripke DF, Weinreb RN. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am J Ophthalmol 2004;138:389-95
   PubMed Web of Science ®Google Scholar
• Quaranta L, Gandolfo F, Turano R, Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma. Invest Ophthalmol Vis Sci 2006;47:2917-23
   PubMed Web of Science ®Google Scholar
• Gonzalez JP, Clissold SP. Ocular levobunolol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1987;34:648-61
   PubMed Web of Science ®Google Scholar
• Woodward DF, Novack GD, Williams LS, Dihydrolevobunolol is a potent ocular beta-adrenoceptor antagonist. J Ocul Pharmacol 1987;3:11-5
   PubMedGoogle Scholar
• Wandel T, Charap AD, Lewis RA, Glaucoma treatment with once-daily levobunolol. Am J Ophthalmol 1986;101:298-304
   PubMed Web of Science ®Google Scholar
• Rakofsky SI, Lazar M, Almog Y, Efficacy and safety of once-daily levobunolol for glaucoma therapy. Can J Ophthalmol 1989;24:2-6
   PubMed Web of Science ®Google Scholar
• Battershill PE, Sorkin EM. Ocular metipranolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in glaucoma and ocular hypertension [review]. Drugs 1988;36:601-15
   PubMed Web of Science ®Google Scholar
• Watson PG, Barnett MF, Parker V, Haybittle J. A 7 year prospective comparative study of three topical beta blockers in the management of primary open angle glaucoma. Br J Ophthalmol 2001;85:962-8
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol 1993;9:373-84
   PubMedGoogle Scholar
• Allen RC, Hertzmark E, Walker AM, Epstein DL. A double-masked comparison of betaxolol vs timolol in the treatment of open-angle glaucoma. Am J Ophthalmol 1986;101:535-41
   PubMed Web of Science ®Google Scholar
• Stewart RH, Kimbrough RL, Ward RL. Betaxolol vs timolol. A six-month double-blind comparison. Arch Ophthalmol 1986;104:46-8
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Caldwell DR, Goode SM, A double-masked three-month comparison between 0.25% betaxolol suspension and 0.5% betaxolol ophthalmic solution. Am J Ophthalmol 1990;110:189-92
   PubMed Web of Science ®Google Scholar
• Nieminen T, Uusitalo H, Turjanmaa V, Association between low plasma levels of ophthalmic timolol and haemodynamics in glaucoma patients. Eur J Clin Pharmacol 2005;61:369-74
   PubMed Web of Science ®Google Scholar
• Kaiserman I, Fendyur A, Vinker S. Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 2009;34:517-22
   PubMed Web of Science ®Google Scholar
• Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging 2007;24:509-28
   PubMed Web of Science ®Google Scholar
• Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998;7:247-52
   PubMed Web of Science ®Google Scholar
• Stamper RL, Wigginton SA, Higginbotham EJ. Primary drug treatment for glaucoma: beta-blockers versus other medications. Surv Ophthalmol 2002;47:63-73
   PubMed Web of Science ®Google Scholar
• Coleman AL, Diehl DL, Jampel HD, Topical timolol decreases plasma high-density lipoprotein cholesterol level. Arch Ophthalmol 1990;108:1260-3
   PubMed Web of Science ®Google Scholar
• Freedman SF, Freedman NJ, Shields MB, Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol 1993;116:600-11
   PubMed Web of Science ®Google Scholar
• Stewart WC, Dubiner HB, Mundorf TK, Effects of carteolol and timolol on plasma lipid profiles in older women with ocular hypertension or primary open-angle glaucoma. Am J Ophthalmol 1999;127:142-7
   PubMed Web of Science ®Google Scholar
• Johns MD, Ponte CD. Acute pulmonary edema associated with ocular metipranolol use. Ann Pharmacother 1995;29:370-3
   PubMed Web of Science ®Google Scholar
• Moorthy RS, Valluri S, Jampol LM. Drug-induced uveitis. Surv Ophthalmol 1998;42:557-70
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A, Casini A. Carbonic anhydrase inhibitors. Med Res Rev 2003;23:146-89
   PubMed Web of Science ®Google Scholar
• Keisu M, Wiholm BE, Ost A, Mortimer O. Acetazolamide-associated aplastic anaemia. J Intern Med 1990;228:627-32
   PubMed Web of Science ®Google Scholar
• Stewart WC, Day DG, Stewart JA, Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% vs placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye (Lond) 2004;18:905-10
   PubMed Web of Science ®Google Scholar
• Hollo G, Chiselita D, Petkova N, The efficacy and safety of timolol maleate versus brinzolamide each given twice daily added to travoprost in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;16:816-23
   PubMed Web of Science ®Google Scholar
• Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19:87-112
   PubMed Web of Science ®Google Scholar
• Pfeiffer N. Dorzolamide: development and clinical application of a topical carbonic anhydrase inhibitor. Surv Ophthalmol 1997;42:137-51
   PubMed Web of Science ®Google Scholar
• Cvetkovic RS, Perry CM. Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003;20:919-47
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-8
   PubMed Web of Science ®Google Scholar
• O'Connor DJ, Martone JF, Mead A. Additive intraocular pressure lowering effect of various medications with latanoprost. Am J Ophthalmol 2002;133:836-7
   PubMed Web of Science ®Google Scholar
• March WF, Ochsner KI. The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension. The Brinzolamide Long-Term Therapy Study Group. Am J Ophthalmol 2000;129:136-43
   PubMed Web of Science ®Google Scholar
• Manni G, Denis P, Chew P, The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
   PubMed Web of Science ®Google Scholar
• Konowal A, Morrison JC, Brown SV, Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol 1999;127:403-6
   PubMed Web of Science ®Google Scholar
• Harris A, Arend O, Kagemann L, Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma. J Ocul Pharmacol Ther 1999;15:189-97
   PubMed Web of Science ®Google Scholar
• Harris A, Arend O, Arend S, Martin B. Effects of topical dorzolamide on retinal and retrobulbar hemodynamics. Acta Ophthalmol Scand 1996;74:569-72
   PubMedGoogle Scholar
• Siesky B, Harris A, Brizendine E, Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 2009;54:33-46
   PubMed Web of Science ®Google Scholar
• Torring MS, Holmgaard K, Hessellund A, The vasodilating effect of acetazolamide and dorzolamide involves mechanisms other than carbonic anhydrase inhibition. Invest Ophthalmol Vis Sci 2009;50:345-51
   PubMed Web of Science ®Google Scholar
• Tielsch JM, Katz J, Sommer A, Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment. Arch Ophthalmol 1995;113:216-21
   PubMed Web of Science ®Google Scholar
• Bonomi L, Marchini G, Marraffa M, Vascular risk factors for primary open angle glaucoma: the Egna-Neumarkt Study. Ophthalmology 2000;107:1287-93
   PubMed Web of Science ®Google Scholar
• Gherghel D, Orgul S, Gugleta K, Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage. Am J Ophthalmol 2000;130:597-605
   PubMed Web of Science ®Google Scholar
• Memarzadeh F, Ying-Lai M, Chung J, Blood Pressure, Perfusion Pressure and Open Angle Glaucoma: The Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2010;51:2872-7
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez M. Effects of dorzolamide 2% added to timolol maleate 0.5% on intraocular pressure, retrobulbar blood flow, and the progression of visual field damage in patients with primary open-angle glaucoma: a single-centre, 4-year, open-label study. Clin Ther 2008;30:1120-34
   PubMed Web of Science ®Google Scholar
• Martinez A, Sanchez-Salorio M. Predictors for visual field progression and the effects of treatment with dorzolamide 2% or brinzolamide 1% each added to timolol 0.5% in primary open-angle glaucoma. Acta Ophthalmol 2010;88:541-52
   PubMed Web of Science ®Google Scholar
• Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol 1996;41(Suppl 1):S9-18
   PubMed Web of Science ®Google Scholar
• Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol 2009;127:402-6
   PubMed Web of Science ®Google Scholar
• Fung AT, Reid SE, Jones MP, Meta-analysis of randomised controlled trials comparing latanoprost with brimonidine in the treatment of open-angle glaucoma, ocular hypertension or normal-tension glaucoma. Br J Ophthalmol 2007;91:62-8
   PubMed Web of Science ®Google Scholar
• thoe Schwartzenberg GW, Buys YM. Efficacy of brimonidine 0.2% as adjunctive therapy for patients with glaucoma inadequately controlled with otherwise maximal medical therapy. Ophthalmology 1999;106:1616-20
   PubMed Web of Science ®Google Scholar
• Rahman MQ, Ramaesh K, Montgomery DM. Brimonidine for glaucoma. Expert Opin Drug Saf 2010;9(3):483-91
   PubMed Web of Science ®Google Scholar
• Rahman MQ, Montgomery DM, Lazaridou MN. Surveillance of glaucoma medical therapy in a Glasgow teaching hospital: 26 years' experience. Br J Ophthalmol 2009;93:1572-5
   PubMed Web of Science ®Google Scholar
• Cantor LB, Safyan E, Liu CC, Batoosingh AL. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial. Curr Med Res Opin 2008;24:2035-43
   PubMed Web of Science ®Google Scholar
• Sherwood MB, Craven ER, Chou C, Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol 2006;124:1230-8
   PubMed Web of Science ®Google Scholar
• Carlsen JO, Zabriskie NA, Kwon YH, Apparent central nervous system depression in infants after the use of topical brimonidine. Am J Ophthalmol 1999;128:255-6
   PubMed Web of Science ®Google Scholar
• Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001;5:281-4
   PubMed Web of Science ®Google Scholar
• Byles DB, Frith P, Salmon JF. Anterior uveitis as a side effect of topical brimonidine. Am J Ophthalmol 2000;130:287-91
   PubMed Web of Science ®Google Scholar
• Harris LS, Shimmyo M, Mittag TW. Cholinesterases and contractility of cat irides: effect of echothiophat iodide. Arch Ophthalmol 1973;89:49-51
   PubMed Web of Science ®Google Scholar
• Naveh-Floman N, Stahl V, Korczyn AD. Effect of pilocarpine on intraocular pressure in ocular hypertensive subjects. Ophthalmic Res 1986;18:34-7
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol 2010;4:1-9
   PubMedGoogle Scholar
• Baudouin C. Side effects of antiglaucomatous drugs on the ocular surface. Curr Opin Ophthalmol 1996;7(2):80-6
   PubMedGoogle Scholar
• Hamacher T, Airksinen J, Saarela V, Efficacy and safety levels of preserved and preservative free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol Suppl (Oxf) 2008;242:14-9
   PubMedGoogle Scholar
• Uusitalo H, Kaarniranta K, Ropo A. Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers. Acta Ophthalmol Suppl (Oxf) 2008;242:7-13
   PubMedGoogle Scholar
• Gross RL, Peace JH, Smith SE, Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma 2008;17(3):217-22
   PubMed Web of Science ®Google Scholar
• Lewis RA, Katz G, Weiss MJ, Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy. J Glaucoma 2007;16(1):98-103
   PubMed Web of Science ®Google Scholar
• Salm M, Belsky D, Sloan FA. Trends in cost of major eye diseases to Medicare, 1991 to 2000. Am J Ophthalmol 2006;142:976-82
   PubMed Web of Science ®Google Scholar
• Rein DB, Zhang P, Wirth KE, The economic burden of major adult visual disorders in the United States. Arch Ophthalmol 2006;124:1754-60
   PubMed Web of Science ®Google Scholar
• Traverso CE, Walt JG, Kelly SP, Direct costs of glaucoma and severity of the disease: a multinational long term study of resource utilisation in Europe. Br J Ophthalmol 2005;89:1245-9
   PubMed Web of Science ®Google Scholar
• Lindblom B, Nordmann JP, Sellem E, A multicentre, retrospective study of resource utilization and costs associated with glaucoma management in France and Sweden. Acta Ophthalmol Scand 2006;84:74-83
   PubMedGoogle Scholar
• Knox FA, Barry M, McGowan B, O'Brien C. The rising cost of glaucoma drugs in Ireland 1996-2003. Br J Ophthalmol 2006;90:162-5
   PubMed Web of Science ®Google Scholar
• Goldberg LD, Walt J. Cost considerations in the medical management of glaucoma in the US: estimated yearly costs and cost effectiveness of bimatoprost compared with other medications. Pharmacoeconomics 2006;24:251-64
   PubMed Web of Science ®Google Scholar
• Strutton DR, Walt JG. Trends in glaucoma surgery before and after the introduction of new topical glaucoma pharmacotherapies. J Glaucoma 2004;13:221-6
   PubMed Web of Science ®Google Scholar
• Thygesen J, Aagren M, Arnavielle S, Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin 2008;24:1763-70
   PubMed Web of Science ®Google Scholar
• Gieser DK, Tracy Williams R, O'Connell W, Costs and utilization of end-stage glaucoma patients receiving visual rehabilitation care: a US multisite retrospective study. J Glaucoma 2006;15:419-25
   PubMed Web of Science ®Google Scholar
• Fiscella RG, Lee J, Davis EJ, Walt J. Cost of illness of glaucoma: a critical and systematic review. Pharmacoeconomics 2009;27:189-98
   PubMed Web of Science ®Google Scholar
• Schmier JK, Halpern MT, Jones ML. The economic implications of glaucoma: a literature review. Pharmacoeconomics 2007;25:287-308
   PubMed Web of Science ®Google Scholar
• Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs 2007;12:313-27
   PubMed Web of Science ®Google Scholar
• Hoyer D, Boddeke HW. Partial agonists, full agonists, antagonists: dilemmas of definition. Trends Pharmacol Sci 1993;14:270-5
   PubMed Web of Science ®Google Scholar
• Liang Y, Li C, Guzman VM, Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J Biol Chem 2003;278:27267-77
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Kashiwagi K, Kashiwagi F, Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest Ophthalmol Vis Sci 1997;38:2772-80
   PubMed Web of Science ®Google Scholar
• Nakajima E, Nakajima T, Minagawa Y, Contribution of ROCK in contraction of trabecular meshwork: proposed mechanism for regulating aqueous outflow in monkey and human eyes. J Pharm Sci 2005;94:701-8
   PubMed Web of Science ®Google Scholar
• Tokushige H, Inatani M, Nemoto S, Effects of topical administration of y-39983, a selective rho-associated protein kinase inhibitor, on ocular tissues in rabbits and monkeys. Invest Ophthalmol Vis Sci 2007;48:3216-22
   PubMed Web of Science ®Google Scholar
• Rao PV, Deng PF, Kumar J, Epstein DL. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest Ophthalmol Vis Sci 2001;42:1029-37
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Inatani M, Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Invest Ophthalmol Vis Sci 2001;42:137-44
   PubMed Web of Science ®Google Scholar
• Pattabiraman PP, Rao PV. Mechanistic basis of Rho GTPase-induced extracellular matrix synthesis in trabecular meshwork cells. Am J Physiol Cell Physiol 2010;298:C749-63
   PubMed Web of Science ®Google Scholar
• Waki M, Yoshida Y, Oka T, Azuma M. Reduction of intraocular pressure by topical administration of an inhibitor of the Rho-associated protein kinase. Curr Eye Res 2001;22:470-4
   PubMed Web of Science ®Google Scholar
• Rosenthal R, Choritz L, Schlott S, Effects of ML-7 and Y-27632 on carbachol- and endothelin-1-induced contraction of bovine trabecular meshwork. Exp Eye Res 2005;80:837-45
   PubMed Web of Science ®Google Scholar
• Kitaoka Y, Kitaoka Y, Kumai T, Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res 2004;1018:111-18
   PubMed Web of Science ®Google Scholar
• Honjo M, Tanihara H, Kameda T, Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci 2007;48:5549-57
   PubMed Web of Science ®Google Scholar
• Lepple-Wienhues A, Stahl F, Willner U, Endothelin-evoked contractions in bovine ciliary muscle and trabecular meshwork: interaction with calcium, nifedipine and nickel. Curr Eye Res 1991;10:983-9
   PubMed Web of Science ®Google Scholar
• Renieri G, Choritz L, Rosenthal R, Effects of endothelin-1 on calcium-independent contraction of bovine trabecular meshwork. Graefes Arch Clin Exp Ophthalmol 2008;246:1107-15
   PubMed Web of Science ®Google Scholar
• Lepple-Wienhues A, Becker M, Stahl F, Endothelin-like immunoreactivity in the aqueous humour and in conditioned medium from cultured ciliary epithelial cells. Curr Eye Res 1992;11:1041-6
   PubMed Web of Science ®Google Scholar
• Noske W, Hensen J, Wiederholt M. Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract. Graefes Arch Clin Exp Ophthalmol 1997;235:551-2
   PubMed Web of Science ®Google Scholar
• Thieme H, Schimmat C, Munzer G, Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest Ophthalmol Vis Sci 2006;47:938-45
   PubMed Web of Science ®Google Scholar
• Wiederholt M, Sturm A, Lepple-Wienhues A. Relaxation of trabecular meshwork and ciliary muscle by release of nitric oxide. Invest Ophthalmol Vis Sci 1994;35:2515-20
   PubMed Web of Science ®Google Scholar
• Tian B, Gabelt BT, Geiger B, Kaufman PL. The role of the actomyosin system in regulating trabecular fluid outflow. Exp Eye Res 2009;88:713-17
   PubMed Web of Science ®Google Scholar
• Rao PV, Shimazaki A, Ichikawa M, Effects of novel ethacrynic acid derivatives on human trabecular meshwork cell shape, actin cytoskeletal organization, and transcellular fluid flow. Biol Pharm Bull 2005;28:2189-96
   PubMed Web of Science ®Google Scholar
• Shimazaki A, Kirihara T, Rao PV, Effects of the new ethacrynic acid oxime derivative SA12590 on intraocular pressure in cats and monkeys. Biol Pharm Bull 2007;30:1445-9
   PubMed Web of Science ®Google Scholar
• Shimazaki A, Ichikawa M, Rao PV, Effects of the new ethacrynic acid derivative SA9000 on intraocular pressure in cats and monkeys. Biol Pharm Bull 2004;27:1019-24
   PubMed Web of Science ®Google Scholar
• Gipson IK, Anderson RA. Actin filaments in cells of human trabecular meshwork and Schlemm's canal. Invest Ophthalmol Vis Sci 1979;18:547-61
   PubMed Web of Science ®Google Scholar
• de Kater AW, Spurr-Michaud SJ, Gipson IK. Localization of smooth muscle myosin-containing cells in the aqueous outflow pathway. Invest Ophthalmol Vis Sci 1990;31:347-53
   PubMed Web of Science ®Google Scholar
• Peterson JA, Tian B, Bershadsky AD, Latrunculin-A increases outflow facility in the monkey. Invest Ophthalmol Vis Sci 1999;40:931-41
   PubMed Web of Science ®Google Scholar
• Okka M, Tian B, Kaufman PL. Effect of low-dose latrunculin B on anterior segment physiologic features in the monkey eye. Arch Ophthalmol 2004;122:1482-8
   PubMed Web of Science ®Google Scholar
• Lepple-Wienhues A, Rauch R, Clark AF, Electrophysiological properties of cultured human trabecular meshwork cells. Exp Eye Res 1994;59:305-11
   PubMed Web of Science ®Google Scholar
• Stumpff F, Strauss O, Boxberger M, Wiederholt M. Characterization of maxi-K-channels in bovine trabecular meshwork and their activation by cyclic guanosine monophosphate. Invest Ophthalmol Vis Sci 1997;38:1883-92
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109-42
   PubMed Web of Science ®Google Scholar
• Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995;268(4 Pt 1):C799-822
   PubMed Web of Science ®Google Scholar
• Stumpff F, Que Y, Boxberger M, Stimulation of maxi-K channels in trabecular meshwork by tyrosine kinase inhibitors. Invest Ophthalmol Vis Sci 1999;40:1404-17
   PubMed Web of Science ®Google Scholar
• Nathanson JA, McKee M. Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye. Invest Ophthalmol Vis Sci 1995;36:1765-73
   PubMed Web of Science ®Google Scholar
• Stumpff F, Wiederholt M. Regulation of trabecular meshwork contractility. Ophthalmologica 2000;214:33-53
   PubMed Web of Science ®Google Scholar
• Siu AW, Maldonado M, Sanchez-Hidalgo M, Protective effects of melatonin in experimental free radical-related ocular diseases. J Pineal Res 2006;40:101-9
   PubMed Web of Science ®Google Scholar
• Gabelt BT, Rasmussen CA, Kaufman PL, Katz B. Effect of the ion channel modulator DNB-001 on ciliary muscle contraction. Invest Ophthalmol Vis Sci 2009;50: E-abstract 4856
   Google Scholar
• Netland PA, Grosskreutz CL, Feke GT, Hart LJ. Color Doppler ultrasound analysis of ocular circulation after topical calcium channel blocker. Am J Ophthalmol 1995;119:694-700
   PubMed Web of Science ®Google Scholar
• Koseki N, Araie M, Tomidokoro A, A placebo-controlled 3-year study of a calcium blocker on visual field and ocular circulation in glaucoma with low-normal pressure. Ophthalmology 2008;115:2049-57
   PubMed Web of Science ®Google Scholar
• Toriu N, Akaike A, Yasuyoshi H, Lomerizine, a Ca2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res 2000;70:475-84
   PubMed Web of Science ®Google Scholar
• Campana G, Bucolo C, Murari G, Spampinato S. Ocular hypotensive action of topical flunarizine in the rabbit: role of sigma 1 recognition sites. J Pharmacol Exp Ther 2002;303:1086-94
   PubMed Web of Science ®Google Scholar
• Maltese A, Bucolo C. Pharmacokinetic profile of topical flunarizine in rabbit eye and plasma. J Ocul Pharmacol Ther 2003;19:171-9
   PubMed Web of Science ®Google Scholar
• Siegner SW, Netland PA, Schroeder A, Erickson KA. Effect of calcium channel blockers alone and in combination with antiglaucoma medications on intraocular pressure in the primate eye. J Glaucoma 2000;9:334-9
   PubMed Web of Science ®Google Scholar
• Wang RF, Gagliuso DJ, Podos SM. Effect of flunarizine, a calcium channel blocker, on intraocular pressure and aqueous humor dynamics in monkeys. J Glaucoma 2008;17:73-8
   PubMed Web of Science ®Google Scholar
• Melena J, Santafe J, Segarra J. The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits. J Pharmacol Exp Ther 1998;284:278-82
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gilbert CM, Smith LM. Sustained reduction of intraocular pressure in humans with the calcium channel blocker verapamil. Am J Ophthalmol 1988;105:155-9
   PubMed Web of Science ®Google Scholar
• Kanellopoulos AJ, Erickson KA, Netland PA. Systemic calcium channel blockers and glaucoma. J Glaucoma 1996;5:357-62
   PubMed Web of Science ®Google Scholar
• Payne LJ, Slagle TM, Cheeks LT, Green K. Effect of calcium channel blockers on intraocular pressure. Ophthalmic Res 1990;22:337-41
   PubMed Web of Science ®Google Scholar
• Segarra J, Santafe J, Garrido M, The topical application of verapamil and nifedipine lowers intraocular pressure in conscious rabbits. Gen Pharmacol 1993;24:1163-71
   PubMedGoogle Scholar
• Erickson KA, Schroeder A, Netland PA. Verapamil increases outflow facility in the human eye. Exp Eye Res 1995;61:565-7
   PubMed Web of Science ®Google Scholar
• Goyal JK, Khilnani G, Sharma DP, Singh J. The hypotensive effect of verapamil eye drops on ocular hypertension. Indian J Ophthalmol 1989;37:176-8
   PubMedGoogle Scholar
• Shayegan MR, Boloorian AA, Kianoush S. Comparative study of topical application of timolol and verapamil in patients with glaucoma within 6 months. J Ocul Pharm Ther 2009;25:551-3
   PubMed Web of Science ®Google Scholar
• He Y, Ge J, Tombran-Tink J. Mitochondrial defects and dysfunction in calcium regulation in glaucomatous trabecular meshwork cells. Invest Ophthalmol Vis Sci 2008;49:4912-22
   PubMed Web of Science ®Google Scholar
• Wang N, Chintala SK, Fini ME, Schuman JS. Activation of a tissue-specific stress response in the aqueous outflow pathway of the eye defines the glaucoma disease phenotype. Nat Med 2001;7:304-9
   PubMed Web of Science ®Google Scholar
• Xue W, Comes N, Borras T. Presence of an established calcification marker in trabecular meshwork tissue of glaucoma donors. Invest Ophthalmol Vis Sci 2007;48:3184-94
   PubMed Web of Science ®Google Scholar
• Gonzalez P, Epstein DL, Borras T. Characterization of gene expression in human trabecular meshwork using single-pass sequencing of 1060 clones. Invest Ophthalmol Vis Sci 2000;41:3678-93
   PubMed Web of Science ®Google Scholar
• Farkas RH, Chowers I, Hackam AS, Increased expression of iron-regulating genes in monkey and human glaucoma. Invest Ophthalmol Vis Sci 2004;45:1410-17
   PubMed Web of Science ®Google Scholar
• Patel BN, Dunn RJ, Jeong SY, Ceruloplasmin regulates iron levels in the CNS and prevents free radical injury. J Neurosci 2002;22:6578-86
   PubMed Web of Science ®Google Scholar
• Thompson K, Menzies S, Muckenthaler M, Mouse brains deficient in H-ferritin have normal iron concentration but a protein profile of iron deficiency and increased evidence of oxidative stress. J Neurosci Res 2003;71:46-63
   PubMed Web of Science ®Google Scholar
• Babizhayev MA, Bunin AYa. Lipid peroxidation in open-angle glaucoma. Acta Ophthalmol (Copenh) 1989;67:371-7
   PubMed Web of Science ®Google Scholar
• Yan DB, Trope GE, Ethier CR, Effects of hydrogen peroxide-induced oxidative damage on outflow facility and washout in pig eyes. Invest Ophthalmol Vis Sci 1991;32:2515-20
   PubMed Web of Science ®Google Scholar
• Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. Curr Neuropharmacol 2008;6:293-310
   PubMed Web of Science ®Google Scholar
• Sharif NA, McLaughlin MA, Kelly CR. AL-34662: a potent, selective, and efficacious ocular hypotensive serotonin-2 receptor agonist. J Ocul Pharmacol Ther 2007;23:1-13
   PubMed Web of Science ®Google Scholar
• Mallorga P, Sugrue MF. Characterization of serotonin receptors in the iris + ciliary body of the albino rabbit. Curr Eye Res 1987;6:527-32
   PubMed Web of Science ®Google Scholar
• Meyer-Bothling U, Bron AJ, Osborne NN. Topical application of serotonin or the 5-HT1-agonist 5-CT intraocular pressure in rabbits. Invest Ophthalmol Vis Sci 1993;34:3035-42
   PubMed Web of Science ®Google Scholar
• Veglio F, De Sanctis U, Schiavone D, Evaluation of serotonin levels in human aqueous humor. Ophthalmologica 1998;212:160-3
   PubMed Web of Science ®Google Scholar
• Chidlow G, Le Corre S, Osborne NN. Localization of 5-hydroxytryptamine1A and 5-hydroxytryptamine7 receptors in rabbit ocular and brain tissues. Neuroscience 1998;87:675-89
   PubMed Web of Science ®Google Scholar
• May JA, Dantanarayana AP, Zinke PW, 1-((S)-2-aminopropyl)-1H-indazol-6-ol: a potent peripherally acting 5-HT2 receptor agonist with ocular hypotensive activity. J Med Chem 2006;49:318-28
   PubMed Web of Science ®Google Scholar
• Lundmark PO, Pandi-Perumal SR, Srinivasan V, Melatonin in the eye: implications for glaucoma. Exp Eye Res 2007;84:1021-30
   PubMed Web of Science ®Google Scholar
• Pintor J, Pelaez T, Hoyle CH, Peral A. Ocular hypotensive effects of melatonin receptor agonists in the rabbit: further evidence for an MT3 receptor. Br J Pharmacol 2003;138:831-6
   PubMed Web of Science ®Google Scholar
• Osborne NN, Chidlow G. The presence of functional melatonin receptors in the iris-ciliary processes of the rabbit eye. Exp Eye Res 1994;59:3-9
   PubMed Web of Science ®Google Scholar
• Wiechmann AF, Wirsig-Wiechmann CR. Melatonin receptor mRNA and protein expression in Xenopus laevis nonpigmented ciliary epithelial cells. Exp Eye Res 2001;73:617-23
   PubMed Web of Science ®Google Scholar
• Martin XD, Malina HZ, Brennan MC, The ciliary body – the third organ found to synthesize indoleamines in humans. Eur J Ophthalmol 1992;2:67-72
   PubMedGoogle Scholar
• Pintor J, Martin L, Pelaez T, Involvement of melatonin MT(3) receptors in the regulation of intraocular pressure in rabbits. Eur J Pharmacol 2001;416:251-4
   PubMed Web of Science ®Google Scholar
• Serle JB, Wang RF, Peterson WM, Effect of 5-MCA-NAT, a putative melatonin MT3 receptor agonist, on intraocular pressure in glaucomatous monkey eyes. J Glaucoma 2004;13:385-8
   PubMed Web of Science ®Google Scholar
• Siu AW, Ortiz GG, Benitez-King G, Effects of melatonin on the nitric oxide treated retina. Br J Ophthalmol 2004;88:1078-81
   PubMed Web of Science ®Google Scholar
• Chen HY, Chen TY, Lee MY, Melatonin decreases neurovascular oxidative/nitrosative damage and protects against early increases in the blood-brain barrier permeability after transient focal cerebral ischemia in mice. J Pineal Res 2006;41:175-82
   PubMed Web of Science ®Google Scholar
• Tomida I, Pertwee RG, Azuara-Blanco A. Cannabinoids and glaucoma. Br J Ophthalmol 2004;88:708-13
   PubMed Web of Science ®Google Scholar
• Pate DW, Jarvinen K, Urtti A, Effect of the CB1 receptor antagonist, SR141716A, on cannabinoid-induced ocular hypotension in normotensive rabbits. Life Sci 1998;63:2181-8
   PubMed Web of Science ®Google Scholar
• Song ZH, Slowey CA. Involvement of cannabinoid receptors in the intraocular pressure-lowering effects of WIN55212-2. J Pharmacol Exp Ther 2000;292:136-9
   PubMed Web of Science ®Google Scholar
• Green K, Pederson JE. Effect of 1-tetrahydrocannabinol on aqueous dynamics and ciliary body permeability in the rabbit. Exp Eye Res 1973;15:499-507
   PubMed Web of Science ®Google Scholar
• Rosch S, Ramer R, Brune K, Hinz B. R(+)-methanandamide and other cannabinoids induce the expression of cyclooxygenase-2 and matrix metalloproteinases in human nonpigmented ciliary epithelial cells. J Pharmacol Exp Ther 2006;316:1219-28
   PubMed Web of Science ®Google Scholar
• Gerra G, Zaimovic A, Gerra ML, Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists. Recent Pat CNS Drug Discov 2010;5(1):46-52
   PubMedGoogle Scholar
• D'Amico DJ, Goldberg MF, Hudson H, ; Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: twelve-month clinical outcomes. Ophthalmology 2003;110:2372-83
   PubMed Web of Science ®Google Scholar
• Robin AL, Clark AF, Covert DW, Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol 2009;147:45-50. e2
   PubMed Web of Science ®Google Scholar
• Husain S, Shearer TW, Crosson CE. Mechanisms linking adenosine A1 receptors and extracellular signal-regulated kinase 1/2 activation in human trabecular meshwork cells. J Pharmacol Exp Ther 2007;320:258-65
   PubMed Web of Science ®Google Scholar
• Crosson CE, Sloan CF, Yates PW. Modulation of conventional outflow facility by the adenosine A1 agonist N6-cyclohexyladenosine. Invest Ophthalmol Vis Sci 2005;46:3795-9
   PubMed Web of Science ®Google Scholar
• Shearer TW, Crosson CE. Adenosine A1 receptor modulation of MMP-2 secretion by trabecular meshwork cells. Invest Ophthalmol Vis Sci 2002;43:3016-20
   PubMed Web of Science ®Google Scholar
• Crosson CE. Adenosine receptor activation modulates intraocular pressure in rabbits. J Pharmacol Exp Ther 1995;273:320-6
   PubMed Web of Science ®Google Scholar
• Avila MY, Stone RA, Civan MM. A1-, A2-, A3-subtype adenosine receptors modulate intraocular pressure in the mouse. Br J Pharmacol 2001;134:241-5
   PubMed Web of Science ®Google Scholar
• Tian B, Gabelt BT, Crosson CE, Kaufman PL. Effects of adenosine agonists on intraocular pressure and aqueous dynamics in cynomolgus monkeys. Exp Eye Res 1997;64:979-89
   PubMed Web of Science ®Google Scholar
• Crosson CE. Intraocular pressure responses to the adenosine agonist cyclohexyladenosine: evidence for a dual mechanism of action. Invest Ophthalmol Vis Sci 2001;42:1837-40
   PubMed Web of Science ®Google Scholar
• Soto D, Comes N, Ferrer E, Modulation of aqueous humor outflow by ionic mechanisms involved in trabecular meshwork cell volume regulation. Invest Ophthalmol Vis Sci 2004;45:3650-61
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Boger III WP. The beta-adrenergic blocking agents and the treatment of glaucoma. Surv Ophthalmol 1979;23:347-62
   PubMed Web of Science ®Google Scholar
• Pintor J. Nucleotides as a new alternative for the treatment of ocular hypertension. Arch Soc Esp Oftalmol 2003;78:295-6
   PubMedGoogle Scholar
• Mediero A, Alarma-Estrany P, Pintor J. New treatments for ocular hypertension. Auton Neurosci 2009;147:14-9
   PubMed Web of Science ®Google Scholar
• Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200
   PubMed Web of Science ®Google Scholar
• Pintor J, Mediero A, Jimenez A, SiRNA in the treatment of ocular hypertension targeting alpha and beta adrenoceptors. Invest Ophthalmol Vis Sci 2006;47: E-abstract 403
   Web of Science ®Google Scholar
• Peral A, Loma P, Mediero A, Effect of several siRNA in the treatment of ocular hypertension and glaucoma. Invest Ophthalmol Vis Sci 2007;48: E-abstract 4808
   Google Scholar
• Jimenez A, Sesto A, Pintor J, Na+/K+ ATPase: A new target for treating ocular hypertension by RNAi. Invest Ophthalmol Vis Sci 2007;48: E-abstract 4809
   Google Scholar
• Yuan C, Zins EJ, Clark AF, Huang AJ. Suppression of keratoepithelin and myocilin by small interfering RNAs (siRNA) in vitro. Mol Vis 2007;13:2083-95
   PubMed Web of Science ®Google Scholar
• Kao HJ, Lin HR, Lo YL, Yu SP. Characterization of pilocarpine-loaded chitosan/Carbopol nanoparticles. J Pharm Pharmacol 2006;58:179-86
   PubMed Web of Science ®Google Scholar
• Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma 2008;17:147-56
   PubMed Web of Science ®Google Scholar
• Monem AS, Ali FM, Ismail MW. Prolonged effect of liposomes encapsulating pilocarpine HCl in normal and glaucomatous rabbits. Int J Pharm 2000;198:29-38
   PubMed Web of Science ®Google Scholar
• Ammar HO, Salama HA, Ghorab M, Mahmoud AA. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride. AAPS PharmSciTech 2009;10:808-19
   PubMed Web of Science ®Google Scholar
• Bertram JP, Saluja SS, McKain J, Lavik EB. Sustained delivery of timolol maleate from poly(lactic-co-glycolic acid)/poly(lactic acid) microspheres for over 3 months. J Microencapsul 2009;26:18-26
   PubMed Web of Science ®Google Scholar
• Aktaş Y, Unlu N, Orhan M, Influence of hydroxypropyl beta-cyclodextrin on the corneal permeation of pilocarpine. Drug Dev Ind Pharm 2003;29:223-30
   PubMed Web of Science ®Google Scholar
• Maestrelli F, Mura P, Casini A, Cyclodextrin complexes of sulfonamide carbonic anhydrase inhibitors as long-lasting topically acting antiglaucoma agents. J Pharm Sci 2002;91:2211-19
   PubMed Web of Science ®Google Scholar
• Nucci C, Bari M, Spano A, Potential roles of (endo)cannabinoids in the treatment of glaucoma: from intraocular pressure control to neuroprotection. Prog Brain Res 2008;173:451-64
   PubMed Web of Science ®Google Scholar
• Schultz CL, Poling TR, Mint JO. A medical device/drug delivery system for treatment of glaucoma. Clin Exp Optom 2009;92:343-8
   PubMed Web of Science ®Google Scholar
• Li CC, Abrahamson M, Kapoor Y, Chauhan A. Timolol transport from microemulsions trapped in HEMA gels. J Colloid Interface Sci 2007;315:297-306
   PubMed Web of Science ®Google Scholar
• Gulsen D, Chauhan A. Ophthalmic drug delivery through contact lenses. Invest Ophthalmol Vis Sci 2004;45:2342-7
   PubMed Web of Science ®Google Scholar
• Inatani M, Tokushige H, Nemoto S, Intraocular pressure-lowering effects of topical administration of Y–39983, a novel selective Rho-associated protein kinase inhibitor. Invest Ophthalmol Vis Sci 2005;46: E-Abstract 3787
   Web of Science ®Google Scholar
• Wang RF, Serle JB, Kopczynski C. Effect of 0.6% AR-12286 on aqueous humor dynamics in 6 normotensive monkey eyes. Invest Ophthalmol Vis Sci 2009;50: E-abstract 1465
   Google Scholar
• Yingling JD, Arnold JJ, deLong MA, IOP-Lowering efficacy and tolerability of AR-12286, a potent kinase inhibitor for the treatment of glaucoma. Invest Ophthalmol Vis Sci 2009;50: E-abstract 4063
   Google Scholar
• Mizuno K, Ohta M, Mori J, Effects of K-115, a Rho-kinase inhibitor, on aqueous humor dynamics in rabbits. Invest Ophthalmol Vis Sci 2008;49: E-abstract 1640
   PubMed Web of Science ®Google Scholar
• Kim N, Crosson C, Supuran C, INO-8875, an adenosine A1 agonist, in development for open-angle glaucoma reduced IOP in three rabbit models. Invest Ophthalmol Vis Sci 2009;50: E-abstract 4061
   Google Scholar
• Bahler CK, Katz B, Fautsch MP. DNB-001 increases trabecular outflow facility in human eyes. Invest Ophthalmol Vis Sci 2009;50: E-abstract 4845
   PubMed Web of Science ®Google Scholar
• Serle JB, Wang RF, Levy B, Katz B. Effects of DNB-001 – a novel ion channel modulator – on intraocular pressure in glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 2009;50: E-abstract 1474
   Google Scholar
• Bosworth CF, Zhang M, Courtney R, Efficacy and safety of PF-03187207, a novel nitric oxide donating prostaglandin F2-alpha analogue, vs. latanoprost in hypertensive eyes. Invest Ophthalmol Vis Sci 2009;50: E-abstract 2481
   Google Scholar
• Landry TA, Dickerson J, Merriam JC. The use of anecortave acetate for refractory, complex glaucoma. Invest Ophthalmol Vis Sci 2008;49: E-abstract 1206
   Google Scholar
• Prata TS, Tavares IM, Mello PAA, Anterior juxtascleral depot of anecortave acetate: intraocular pressure reduction in different types of glaucoma. Invest Ophthalmol Vis Sci 2008;49: E-abstract 1205
   Google Scholar
• Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol 2009;148:186-191. e2
   PubMed Web of Science ®Google Scholar
• Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006;17:190-5
   PubMed Web of Science ®Google Scholar
• Fuchshofer R, Tamm ER. Modulation of extracellular matrix turnover in the trabecular meshwork. Exp Eye Res 2009;88:683-8
   PubMed Web of Science ®Google Scholar
• Agarwal R, Agarwal P. Future target molecules in antiglaucoma therapy: TGF-beta may have a role to play. Ophthalmic Res 2010;43:1-10
   PubMed Web of Science ®Google Scholar